MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
9.35
+0.24
+2.63%
Opening 10:46 04/01 EDT
OPEN
9.23
PREV CLOSE
9.11
HIGH
9.60
LOW
9.05
VOLUME
217.08K
TURNOVER
--
52 WEEK HIGH
11.61
52 WEEK LOW
1.340
MARKET CAP
495.22M
P/E (TTM)
-12.0770
1D
5D
1M
3M
1Y
5Y
1D
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201
TipRanks · 1d ago
Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target
Benzinga · 1d ago
Immix Biopharma Is Maintained at Outperform by Mizuho
Dow Jones · 2d ago
Immix Biopharma Price Target Raised to $15.00/Share From $14.00 by Mizuho
Dow Jones · 2d ago
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $15
Benzinga · 2d ago
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
TipRanks · 2d ago
Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial
Reuters · 2d ago
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.